Explore psychedelic drug development via our Q1'25 šŸŽÆ Bullseye Chart.
You are currently viewing CB Therapeutics granted a new patent that will help further provide eco-conscious avenues for psychedelic research

CB Therapeutics granted a new patent that will help further provide eco-conscious avenues for psychedelic research

CARLSBAD, Calif., May 19, 2022 (GLOBE NEWSWIRE) — CB Therapeutics (the ā€œCompanyā€), a biotechnology and precision fermentation company focused on using cellular agriculture to produce environmentally-friendly products for human health, has been granted a new patent covering the use of microorganisms to produce tryptamines and their analogs, such as psilocybin and various other molecules found in ā€œmagicā€ mushrooms. The patent marks yet another milestone for the Company in its journey to create safe, sustainable, and scalable compounds for various industries, researchers and clinicians.

Source link

Leave a Reply

Subscribe to Our Free Newsletter